1. Home
  2. VRTX vs SONY Comparison

VRTX vs SONY Comparison

Compare VRTX & SONY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • SONY
  • Stock Information
  • Founded
  • VRTX 1989
  • SONY 1946
  • Country
  • VRTX United States
  • SONY Japan
  • Employees
  • VRTX N/A
  • SONY N/A
  • Industry
  • VRTX EDP Services
  • SONY Consumer Electronics/Appliances
  • Sector
  • VRTX Technology
  • SONY Consumer Staples
  • Exchange
  • VRTX Nasdaq
  • SONY Nasdaq
  • Market Cap
  • VRTX 128.5B
  • SONY 109.6B
  • IPO Year
  • VRTX 1991
  • SONY 1958
  • Fundamental
  • Price
  • VRTX $467.01
  • SONY $18.99
  • Analyst Decision
  • VRTX Buy
  • SONY Strong Buy
  • Analyst Count
  • VRTX 29
  • SONY 3
  • Target Price
  • VRTX $513.58
  • SONY $24.00
  • AVG Volume (30 Days)
  • VRTX 1.2M
  • SONY 3.0M
  • Earning Date
  • VRTX 11-04-2024
  • SONY 11-08-2024
  • Dividend Yield
  • VRTX N/A
  • SONY 2.94%
  • EPS Growth
  • VRTX N/A
  • SONY 28.85
  • EPS
  • VRTX N/A
  • SONY 1.28
  • Revenue
  • VRTX $10,625,800,000.00
  • SONY $91,758,848,854.00
  • Revenue This Year
  • VRTX $12.20
  • SONY N/A
  • Revenue Next Year
  • VRTX $8.31
  • SONY $1.59
  • P/E Ratio
  • VRTX N/A
  • SONY $14.47
  • Revenue Growth
  • VRTX 10.06
  • SONY 10.36
  • 52 Week Low
  • VRTX $346.29
  • SONY $15.02
  • 52 Week High
  • VRTX $519.88
  • SONY $20.67
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 42.88
  • SONY 56.92
  • Support Level
  • VRTX $489.02
  • SONY $18.41
  • Resistance Level
  • VRTX $519.88
  • SONY $20.67
  • Average True Range (ATR)
  • VRTX 14.86
  • SONY 0.32
  • MACD
  • VRTX -2.67
  • SONY 0.09
  • Stochastic Oscillator
  • VRTX 14.49
  • SONY 45.98

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About SONY Sony Group Corporation

Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments.

Share on Social Networks: